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1. Introduction
The prevalence of chronic kidney disease (CKD) is increasing, and CKD patients are at risk
for severe adverse outcomes such as progressive loss of kidney function, cardiovascular
(CV) disease, and premature death [1]. CKD-Mineral and Bone Disorder (CKD-MBD) is the
clinical syndrome that develops as a systemic disorder of bone and mineral metabolism due
to CKD, which is manifested by abnormalities in bone and mineral metabolism [1]. Altera‐
tions in calcium and phosphate metabolism that are frequently observed in secondary hy‐
perparathyroidism of uremia (SHPT), particularly in patients with maintenance
hemodialysis, contribute to ectopic calcification, CV disease, and the risk of death [2].
SHPT is associated with various bone diseases including osteitis fibrosa caused by excessive
secretion of parathyroid hormone (PTH), osteomalacia, adynamic bone disease, and combi‐
nations thereof; these diseases are collectively called renal osteodystrophy (ROD). In addi‐
tion, ectopic calcifications such as soft-tissue and vascular calcifications are observed in
patients with long-standing CKD. These patients are characterized by calcification of the
vascular media, which is called Mönckeberg medial calcific sclerosis, and vascular intima,
which is typically triggered by abnormal calcium and phosphorous metabolism due to
SHPT [3]. Calcification of the vascular media is a particularly important factor for predicting
CV mortality in dialysis patients. Elevation of the serum calcium × phosphate product also
increases the relative mortality risk. The abovementioned facts suggest that the pathology of
CKD-MBD should be fully elucidated to prepare an appropriate treatment plan.
© 2013 Imanishi et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Calcium and phosphate homeostasis
Small changes in extracellular fluid calcium concentration have major effects on muscle con‐
traction and neuronal excitability, as well as numerous cellular functions such as cell divi‐
sion, cell adhesion, plasma membrane integrity, and coagulation. However, the changes in
serum phosphate concentration are asymptomatic in normally functioning kidneys. Severe
chronic depletion may cause anorexia, muscle weakness, and osteomalacia. Hyperphospha‐
temia is also asymptomatic, although symptoms of hypocalcemia, including tetany, can oc‐
cur when concomitant hypocalcemia is present.
Parathyroid hormone (PTH), the active form of vitamin D (1,25-dihydroxyvitamin D; 1,25-
(OH)2D), and fibroblast growth factor (FGF)-23, are the principal physiologic regulators of
calcium and phosphate homeostasis in humans [4,5] (Figure 1). Feedback loops exist be‐
tween ionized calcium (Ca2+), phosphate, 1,25-(OH)2D, FGF-23, and PTH.
Figure 1. Feedback loops in calcium ion (Ca2+) and phosphate (P) homeostasis [4,5], modified from a previous report
[8]. Feedback loops exist between Ca2+, P, 1,25-dihydroxyvitamin D (1,25-(OH)2D), fibroblast growth factor 23
(FGF-23), and parathyroid hormone (PTH). Ca2+, 1,25-(OH)2D, and FGF-23 suppress PTH secretion, whereas P overload
accelerates it. P overload does not always cause the elevation of serum phosphate, with the exception of some condi‐
tions such as chronic kidney disease.
2.1. Parathyroid Hormone (PTH)
The extracellular fluid Ca2+ concentration is the primary regulator of the rapid (in minutes)
synthesis and secretion of PTH. An inverse relationship was observed between the extracel‐
lular fluid Ca2+ concentration and PTH secretion from parathyroid cells in vitro [6] (Figure 2).
Hypersecretion of PTH causes hypophosphatemia due to hyperphosphaturia in normally
functioning kidneys; however, it leads to hyperphosphatemia by mobilization of phosphate
from skeletal tissues in CKD, particularly in hemodialysis patients.
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2.2. 1,25-dihydroxyvitamin D (1,25-(OH)2D)
In contrast to the rapid action of PTH, 1,25-(OH)2D contributes to long-term calcium homeo‐
stasis. 1,25-(OH)2D also elevates serum phosphate concentration by promoting incremental
intestinal phosphate absorption.
Figure 2. Pathogenesis of secondary hyperparathyroidism of uremia (SHPT) [56], modified from a previous report [26].
The analyses of PTH secretions inhibited by extracellular calcium in vitro revealed the sigmoidal relationship of the PTH
−calcium relationship. Setpoint, the calcium concentration causing half-maximal inhibition of PTH secretion, is an indi‐
cator of sensitivity of parathyroid cells to extracellular calcium by CaR. (A) The relationship in healthy subjects was fit‐
ted to a symmetrical sigmoidal curve. (B) The normal sigmoidal curve will shift upward when the secretory cell number
is increased, without changing its setpoint. (C) An altered sigmoidal curve is observed in human parathyroid adeno‐
mas, refractory SHPT, by changing the setpoint to the right. In the case of severe setpoint shift, PTH secretion is persis‐
tent even at high calcium concentration: so-called ‘autonomous’ PTH secretion. An altered PTH−calcium relationship
was also observed in PTH-cyclin D1 transgenic mice [4, 52]. (D) Administration of cinacalcet or activating mutation of
CaR observed in autosomal dominant hypocalcemia increases the CaR sensitivity to serum calcium. Activations of CaR
result in the PTH−calcium relationship curve moving to the left.
2.3. Fibroblast Growth Factor 23 (FGF-23)
FGF-23, a member of the FGF family, is a major phosphaturic factor in the development of
hypophosphatemic rickets/osteomalacia, including X-linked hypophosphatemic rickets
(XLH) and oncogenic osteomalacia [7]. FGF-23 suppresses both PTH secretion and its ex‐
pression in parathyroid cells [8]. PTH also stimulated FGF-23 expression and its secretion in
bone [9], suggesting that a negative feedback loop exists between PTH and FGF-23 [4,5]
(Figure 1).
3. Receptors in parathyroid cells
The 3 parathyroid cell receptors that are important in calcium and phosphate homeosta‐
sis include the calcium-sensing receptor (CaR) and the FGF receptor (FGFR)-Klotho com‐
plex  located  on  the  cell  surface  and  nuclear  vitamin  D  receptor  (VDR)  (Table  1).  CaR
Pathogenesis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder
http://dx.doi.org/10.5772/52934
83
and VDR are target molecules for the treatment of hyperfunctioning parathyroid diseases
in CKD patients.
Receptor Location
1. Vitamin D receptor; VDR cell nucleus
2. Calcium-sensing receptor; CaR cell membrane
3. FGFR-Klotho complex cell membrane
Table 1. Receptors in parathyroid cells
3.1. Calcium-Sensing Receptor (CaR)
CaR contains a characteristic G protein-coupled receptor 7 membrane-spanning motif with
an unusually large N-terminal extracellular domain, which was cloned in 1993 [10]. Posi‐
tional cloning approaches have clarified that loss-of-function mutations in the CaR gene
cause familial hypocalciuric hypercalcemia (heterozygous mutations) and neonatal severe
hyperparathyroidism (homozygous mutations) [11].
Heterozygous CaR knockout mice exhibited a phenotype that was similar to that of familial
hypocalciuric hypercalcemia [12]. Serum PTH levels were inappropriately elevated; howev‐
er, the parathyroid glands were not enlarged in the heterozygous knockout mice. Homozy‐
gous knockout mice demonstrated markedly elevated serum calcium and PTH
concentrations, retarded growth, and premature death [12]. These symptoms are similar to
those of human neonatal severe hyperparathyroidism.
Synthetic allosteric modulators of CaR have been developed that act as either positive mod‐
ulators (calcimimetics) or negative modulators (calcilytics). These ligands do not activate the
wild-type receptor directly, but rather shift the PTH-calcium sigmoidal curves to the left or
right, respectively (Figure 2).
3.2. Vitamin D Receptor (VDR)
1,25-(OH)2D is the major steroid hormone that plays a crucial role in calcium and phosphate
homeostasis, and its actions are mediated by VDR. Hereditary hypocalcemic vitamin D-re‐
sistant rickets (HVDDR) is an autosomal recessive disorder that is caused by inactivating
mutations in the VDR gene, resulting in target tissue insensitivity to 1,25-(OH)2D [13].
VDR knockout mice exhibit hypocalcemia, hypophosphatemia, rickets, alopecia, and hyper‐
parathyroidism with enlarged parathyroid glands, similar to HVDDR [14,15]. Tissue-specif‐
ic ablation of VDR in parathyroid tissue results in decreased parathyroid CaR expression
and moderately increased basal PTH levels; however, no significant abnormalities in PTH-
calcium sigmoidal curves were observed [16], suggesting limited roles of VDR in parathy‐
roid pathophysiology.
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3.3. FGF Receptor (FGFR)-Klotho complex
Klotho, which is expressed in kidney and pituitary and parathyroid glands, converts FGFR1,
a canonical receptor for various FGFs, into an FGF-23-specific receptor [17]. FGF-23 null
mice exhibit various senescence-like phenotypes such as a short lifespan, infertility, atrophy
of the lymphopoietic and reproductive organs, decreased bone mineral density, and ectopic
calcification. This phenotype is similar to that of Klotho-deficient mice [18], suggesting that
FGF-23 signaling is Klotho dependent.
4. Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD)
It is widely known that the progression of CKD increases mortality risk and the incidence of
CV events [19]. Hyperphosphatemia is a critical electrolyte abnormality in patients with
CKD-mineral and bone disorder (CKD-MBD) [20]. Even though hemodialysis or peritoneal
dialysis is given to hyperphosphatemia patients with advanced CKD, these therapies are in‐
effective due to insufficient phosphorus-removal ability.
4.1. Calcium and phosphate metabolism in CKD-MBD
FGF-23 is involved in abnormal calcium and phosphate metabolism in CKD patients as the
disease progresses. A cross-sectional study of 80 CKD patients revealed decreases in esti‐
mated GFR (eGFR), serum calcium, and 1,25-(OH)2D levels as well as increases in serum P,
fractional excretion of phosphate, PTH, and FGF-23 [21].
Further  study  of  the  abovementioned  data  revealed  an  increase  in  serum  FGF-23  level
(eGFR 45~60  mL/min),  which  is  an  independent  predictor  of  the  fractional  excretion  of
phosphate,  far  earlier  than the  increase  in  serum phosphate  levels  (eGFR <30  mL/min).
The increase in FGF-23 level  is  one of  the greatest  independent  predictors  of  decreased
1,25-(OH)2D level, independent of serum phosphate and eGFR. This suggests that the in‐
crease in FGF-23 level  is  the main reason for the decrease in 1,25-(OH)2D level  in CKD
progression.  Thus,  the  increase  in  FGF-23  level  compensates  for  the  increase  in  the  se‐
rum phosphate levels caused by the decrease in nephrons associated with CKD progres‐
sion by increasing the fractional excretion of phosphate. However, the increase in FGF-23
level also decreases the level of 1,25-(OH)2D, which promotes PTH secretion and acceler‐
ates the progression of SHPT.
4.2. Vascular calcification in CKD-MBD
In an experiment using human vascular smooth muscle cells, inorganic phosphate transport
into the cells via type III Na-Pi co-transporter (Pit-1) increased as the extracellular phosphate
concentration increased. The increase in the intracellular phosphate concentration induced
the expression of marker genes of apoptosis and osteogenic/chondrogenic cells in the vascu‐
lar wall cells, which resulted in calcification [22]. This finding also implies a relationship be‐
tween blood vessel calcification and phosphate levels in vitro.
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Maintenance hemodialysis patients often develop blood vessel calcification, which is direct‐
ly proportional to the duration of dialysis, irrespective of their age; this condition is charac‐
terized by calcification of the vascular media called Mönckeberg sclerosis rather than
calcification of the vascular intima. The onset of blood vessel calcification in dialysis patients
is mainly caused by abnormal calcium and phosphate metabolism due to SHPT [3], which is
one of the signs of CKD-MBD. Calcification of the iliac artery [23] and abdominal aorta [24]
are critical predictors of CV mortality in dialysis patients.
4.3. Renal Osteodystrophy (ROD)
ROD is a mineral and bone disorder that occurs as a complication of CKD, which exacer‐
bates bone fragility and fracture [1]. The serum phosphorus concentration was significantly
related to hospitalization for fracture [2]. Old age, dialysis vintage, female gender, white
race, and lower body weight were significantly associated with an increased risk of fracture-
related hospitalization.
In CKD patients, ROD manifests as alterations in bone morphology, such as osteitis fibrosa
cystica, mild hyperparathyroid-related bone disease, osteomalacia, adynamic bone disease,
and mixed uremic osteodystrophy. ROD represents histopathologic changes observed in
bone and is typically characterized by changes in bone turnover, volume, and mineraliza‐
tion (TMV) (Table 2). The TMV classification, assessed by histomorphometry, provides a
clinically relevant description of the underlying bone pathology and helps define the patho‐
physiology of the disease.
Turnover Mineralization Volume
Low Normal Low
Normal Abnormal Normal
High High
TMV: bone turnover, mineralization, and volume
Table 2. TMV classification for renal osteodystrophy (ROD) [1]
5. Pathogenesis of Secondary Hyperparathyroidism of uremia (SHPT)
PTH secretion increases when the glomerular filtration rate (GFR) of CKD patients decreases
to 40–50 mL/min or less [25]. Renal impairment decreases urinary phosphate excretion,
gradually leading to hyperphosphatemia. Phosphate accumulation in the body reduces 1α
hydroxylase activity in the kidneys and suppresses vitamin D activation, which results in
decreased serum active vitamin D (1,25-(OH)2D) levels [26] (Figure 3). Hyperphosphatemia
causes hypocalcemia by directly affecting the parathyroid glands; moreover, impaired vita‐
min D activation promotes PTH synthesis and secretion [27], which induces the proliferation
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of parathyroid cells and parathyroid hyperplasia. This change stimulates excessive PTH ac‐
tivity and allows phosphates of the bone to move into the blood, exacerbating the hyper‐
phosphatemia. Even though hemodialysis or peritoneal dialysis is given to
hyperphosphatemia patients with advanced CKD, these therapies are ineffective due to the
patients’ insufficient phosphate-removal ability.
Figure 3. Pathogenesis of parathyroid tumorigenesis [4]. (A) A set of somatic mutations (hits) confers a growth ad‐
vantage to an affected cell. Monoclonal growth renders the cells susceptible to more somatic mutations (hits), which
leads to clonal evolution. (B) A uremic status such as chronic hypocalcemia, decreased levels of serum 1,25-(OH)2D,
and hyperphosphatemia stimulates parathyroid cell growth and leads to multi-glandular polyclonal hyperplasia. These
hyperplastic parathyroid cells are susceptible to somatic mutations (hits), resulting in monoclonal growth.
In the earliest stages of CKD, the parathyroid glands undergo multi-glandular generalized
hyperplasia, presumably a true polyclonal expansion, in response to stimuli that may in‐
clude chronic hypocalcemia, decreased levels of serum 1,25-(OH)2D, and hyperphosphate‐
mia. However, in the late stage of this disease, usually after many years of dialysis
treatment, a subset of patients develop refractory SHPT in which excessive PTH secretion no
longer responds to physiological influences or standard medical therapy. Therefore, medi‐
cally refractory SHPT is quite different from the readily managed SHPT, which is character‐
ized by an abnormal PTH-calcium secretory relationship [28,29], is “autonomous,” and is
typically treated by surgical parathyroidectomy. VDR [30] and CaR [31] expression was re‐
duced in the parathyroid tumors of these patients.
The majority of surgically removed uremic parathyroid glands were confirmed to be mono‐
clonal neoplasms by X-chromosome inactivation analysis [32]. This monoclonality implies
that somatic mutation of certain genes controlling cell proliferation occurred in a single par‐
athyroid cell, conferring a selective growth advantage upon it and its progeny (Figure 4).
Distinct chromosomal abnormalities in sporadic parathyroid adenomas [33] and uremia-as‐
sociated parathyroid tumors [34] revealed that the molecular pathogenesis of tumorigenesis
in these 2 categories of parathyroid tumors was different. However, the major genes in‐
volved in the pathogenesis of SHPT remain unknown.
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Figure 4. The sigmoidal curve of the PTH-calcium relationship [56]. The analyses of PTH secretions inhibited by extrac‐
ellular calcium in vitro revealed a sigmoidal PTH-calcium relationship [6]. The setpoint, the calcium concentration caus‐
ing half-maximal inhibition of PTH secretion, is an indicator of sensitivity of parathyroid cells to extracellular calcium by
the calcium receptor (CaR). (A) This relationship in healthy subjects was fitted to a symmetrical sigmoidal curve. (B) The
normal sigmoidal curve will shift upward when secretory cell number is increased without changing its setpoint. (C)
An altered sigmoidal curve is observed in human parathyroid adenomas, refractory secondary hyperparathyroidism of
uremia, with the setpoint shifting to the right. In the case of severe setpoint shift, PTH secretion is persistent even at
high calcium concentrations, due to so-called “autonomous” PTH secretion. An altered PTH-calcium relationship was
also observed in PHPT model mice [4,52]. (D) Administration of calcimimetics or the presence of an activating muta‐
tion of CaR in autosomal dominant hypocalcemia (ADH) patients [57] increased the sensitivity of CaR to serum calcium
concentration in parathyroid cells. Activations of CaR result in a shift of the PTH-calcium relationship curve to the left.
Reduced expression of Klotho and FGFR1 was noted in the hyperplastic parathyroid glands
of SHPT patients [35], suggesting that reduced FGF-23 signaling in parathyroid cells plays a
role in the development of SHPT. However, some studies of Klotho expression in uremic an‐
imals reported conflicting results [36-38]. Further studies are necessary to clarify the role of
FGFR-Klotho signaling in uremic parathyroid glands.
6. Guidelines for CKD-MBD
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI,
USA) published the “K/DOQI clinical practice guidelines for bone metabolism and disease
in chronic kidney disease” in 2003 as evidence-based clinical practice guidelines [39]. In
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2005, according to “Definition and classification of chronic kidney disease: a position state‐
ment from Kidney Disease: Improving Global Outcomes (KDIGO),” the term CKD-MBD
was proposed, stating that the importance of bone and mineral metabolism in CKD should
be conceptualized in terms of prognosis [20]; this means that bone and mineral metabolism
in CKD can be considered a systemic disease. In 2009, KDIGO proposed the current clinical
practice guidelines [40], which have been adopted in clinical settings.
7. Treatment of CKD-MBD
The risk of all-cause mortality and CV events in patients with CKD-MBD on maintenance
hemodialysis is well established. A greater mortality risk associated with phosphate, fol‐
lowed by calcium and PTH levels, was reported [41]. These 3 parameters are not only the
best surrogate markers but also the best targets for CKD-MBD treatment.
7.1. Phosphate-binding agents
All-cause mortality increased regardless of whether serum phosphate levels were higher or
lower than the reference value, exhibiting a U-shaped distribution [42]. However, mainte‐
nance dialysis patients in stable condition are likely to develop hyperphosphatemia, indicat‐
ing that hyperphosphatemia treatment should be a primary target. Diet therapy is the first-
line therapy that can sufficiently control serum phosphate levels. If it is insufficient,
phosphate binders are administered orally. Calcium-containing phosphate binder (e.g., cal‐
cium carbonate) have been used for a long time. However, concomitant use of active vita‐
min D products can lead to the development of hypercalcemia and increase serum calcium ×
phosphate product levels. Therefore, non-calcium-containing phosphate binder such as sev‐
elamer hydrochloride and lanthanum carbonate are widely used.
Although hyperphosphatemia is a risk factor for mortality in dialysis patients, the effects of
restricting phosphorus intake in these patients are unclear. When oral phosphorus intake is
controlled, serum phosphate levels decrease, but poor nutritional status occurs as well.
Thus, it is difficult to judge the true effect of the restriction of phosphorus intake, although
studies using phosphate binders have been performed.
The Accelerated Mortality on Renal Replacement (ArMORR) study is a 1-year observational
cohort study of 10,044 hemodialysis patients in 1,056 medical institutions in the US. Accord‐
ing to this study, the 1-year survival rate of 3,555 patients prescribed phosphate binders be‐
fore or within 90 days of initiating dialysis was higher than that of 5,055 patients who were
not treated with these agents during the same period [43]. That study also compared surviv‐
al in a subcohort of patients treated and not treated with phosphate binders matched by
their baseline serum phosphate levels (i.e., a propensity score matched cohort study) and
concluded that the survival rate was greater in the treated group, demonstrating the positive
effect of these agents on the survival rate (Figure 5).
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Figure 5. Survival of treated and untreated patients of the overall propensity score-matched cohort in the Accelerated
Mortality on Renal Replacement (ArMORR) study [43]. A 1-year observational cohort study involving 10,044 dialysis
patients in 1,056 medical institutions in the US studied the relationship between the effect of phosphate binders be‐
fore and within 90 days of initiating dialysis and 1-year survival rate. The survival rate was greater in the group treated
with phosphate binders. The subcohort study of patients treated and untreated with phosphate binders, matched by
their baseline serum phosphate levels (i.e., the propensity score matched cohort), also demonstrated that the treated
group had a better survival rate, demonstrating the positive effect of these agents on survival.
Many studies on maintenance dialysis patients have been performed. What about studies on
patients who have just started dialysis? The Choices for Healthy Outcomes in Caring for
End-Stage Renal Disease (CHOICE) study is a prospective cohort study of patients who just
started hemodialysis or peritoneal dialysis [44]. That study included 1,007 subjects, 98% of
whom were enrolled in the study within 4 months. The study was started at a median of 45
days after the patients started dialysis. The results obtained 2.5 years later indicated that
higher serum phosphate levels were an independent predictor of all-cause mortality. In ad‐
dition, the relative risk of all-cause mortality was also high in subjects whose serum phos‐
phate levels were high at the start of dialysis but decreased 6 months later. The
abovementioned results suggest that the serum phosphate level at the start of dialysis is an
important prognostic factor.
7.2. Vitamin D Receptor Activators (VDRAs)
Active vitamin D products inhibit PTH gene transcription and secretion as well as parathy‐
roid cell proliferation in the parathyroid glands. Daily oral administration of 1α-(OH)D3 (al‐
facalcidol), 1,25-(OH)2D3 (calcitriol), and/or 26,27-hexafluoro-1,25-(OH)2D3 (falecalcitriol) is
performed to prevent the progression of SHPT. However, the effect of this treatment is in‐
sufficient, because the expression of vitamin D receptor (VDR) decreases in uremia-associat‐
ed parathyroid tumor.
A rapid increase in serum 1,25-(OH)2D levels due to intravenous administration of calcitriol
can partly inhibit the synthesis and secretion of PTH in parathyroid cells, which express less
VDR. Furthermore, 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol, OCT), an analog in
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which the carbon of calcitriol at position 22 is replaced with an oxygen atom, is character‐
ized by a weaker intestinal calcium absorption capacity than that with the inhibition of PTH
secretion. Therefore, it is unlikely to cause hypercalcemia.
Among the subjects in the ArMORR study who were not treated with active vitamin D ana‐
logs, 25OHD level, which exhibits individual nutritional vitamin D status, was elevated,
while both all-cause mortality and CV mortality decreased (Figure 6). Furthermore, all-cause
mortality and CV mortality decreased significantly in the subjects administered VDRA, re‐
gardless of 25OHD level, indicating that the prognosis of VDRA improved in the mainte‐
nance dialysis patients [45].
Figure 6. Multivariate-adjusted ORs of 90-day all-cause and cardiovascular (CV) mortality in the ArMORR study [45].
The ArMORR study involved 825 maintenance dialysis patients who were not treated with active vitamin D before or
within 90 days of initiating dialysis to evaluate the effect of active vitamin D products on prognosis. 25OHD, which
indicates the individual nutritional vitamin D status, was high in the subjects who were not treated with active vitamin
D, while all-cause mortality and CV mortality decreased. Furthermore, all-cause mortality and CV mortality decreased
significantly in the subjects administered with VDRA regardless of 25OHD levels.
7.3. Calcimimetics
Information on extracellular Ca2+ levels is transferred to parathyroid cells via CaR in the par‐
athyroid glands, which control PTH secretion. Multivalent cations including Ca2+, Mg2+, and
Gd3+ act on CaR as agonists. However, calcimimetics do not act as agonists but allosterically
increase the sensitivity of CaR to multivalent cations [46].
Calcimimetic cinacalcet suppressed PTH secretion in cultured human pathological parathy‐
roid cells obtained from primary hyperparathyroidism (PHPT) and SHPT patients, which
exhibit reduced expression of CaR, the target molecule of cinacalcet [47]. These data support
the clinical application of cinacalcet for PHPT and SHPT treatment.
Calcimimetic cinacalcet suppressed not only PTH secretion but also parathyroid cell prolif‐
eration, which prevented parathyroid hyperplasia in vivo in 5/6-nephrectomized rats, the an‐
imal model of SHPT [48]. Calcimimetic tecalcet also reversed the development of osteitis
fibrosa in the SHPT rats [49]. In a relative hypocalcemic to normocalcemic environment, cal‐
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cimimetics effectively suppress PTH secretion and parathyroid cell proliferation. Interest‐
ingly, cinacalcet suppressed aortic calcification in SHPT rats by decreasing serum PTH,
calcium, and phosphate concentrations [50], suggesting that cinacalcet may be beneficial for
the prevention of ectopic calcification as well as the improvement of morbidity and mortali‐
ty in patients with CKD.
Cinacalcet also suppressed PTH secretion in PTH-cyclin D1  transgenic mice [51]. PTH-cy‐
clin D1  transgenic mice are an animal model of PHPT that overexpress the cyclin D1  on‐
cogene  in  the  parathyroid  glands,  which  was  accomplished  by  using  a  transgene  that
mimics the human PTH-cyclin D1 gene rearrangement [52]. Tissue-specific overexpression
of  the  cyclin  D1  oncogene  not  only  resulted  in  abnormal  parathyroid  cell  proliferation
but, notably, also led to the development of biochemical hyperparathyroidism with char‐
acteristic bone abnormalities.
Hypercalcemia may stimulate considerable CaR activity, as the expression of CaR was sup‐
pressed in the parathyroid glands of these mice [52]. These conditions are compatible with
the status observed in refractory SHPT patients undergoing maintenance hemodialysis. Al‐
though older transgenic mice exhibited advanced hyperparathyroidism caused by severely
decreased CaR expression, cinacalcet suppressed both serum calcium and PTH concentra‐
tions [51] and parathyroid growth [53]. CaR is a potentially useful target for a therapeutic
agent such as cinacalcet to suppress PTH secretion, despite the reduction in CaR expression
observed in the parathyroid glands of patients with advanced PHPT and SHPT.
A meta-analysis of 8 randomized, double-blind, placebo-controlled trials (total number of
subjects, 1,429) revealed that calcimimetics significantly decrease serum PTH, serum calci‐
um, and serum phosphate levels, in turn significantly decreasing the serum calcium × phos‐
phate product [54] (Figure 7). The improvements in the abovementioned serum parameters
due to calcimimetics were clarified in the analysis. However, no improvement in all-cause
mortality or decreased parathyroidectomy was observed, and the incidence of bone fracture
was not studied.
An observational study was performed using the United States Renal Data System to deter‐
mine all-cause and CV mortality. Time-dependent Cox proportional hazards modeling
found that all-cause and CV mortality rates were significantly reduced in cinacalcet-treated
patients relative to those that did not receive cinacalcet treatment. Although this study re‐
vealed a significant survival benefit associated with cinacalcet, randomized clinical trials are
needed to confirm a survival advantage associated with calcimimetics [55].
7.4. Percutaneous Ethanol Injection Therapy (PEIT)
Percutaneous ethanol injection therapy (PEIT) is performed by directly injecting ethanol into
a parathyroid tumor under ultrasound guidance to necrotize parathyroid tumor cells. Its
merits include minimal invasiveness and multiple sessions. However, the technique some‐
times induces recurrent laryngeal nerve paralysis, making it inapplicable in the presence of
recurrent laryngeal nerve paralysis in the contralateral parathyroid gland.
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Figure 7. Positive effect of cinacalcet on serum parameters in the meta-analysis of 8 randomized, double-blind, place‐
bo-controlled trials (total number of subjects, 1,429) [54] Cinacalcet significantly decreased serum PTH, calcium, and
phosphate levels, thereby significantly decreasing the serum calcium × phosphate product; WMD: weighted mean dif‐
ference, SD: standard deviation, CI: confidence interval
7.5. Parathyroidectomy (PTX)
PTX is recommended for the treatment of SHPT that is resistant to medical management.
Isolation of the parathyroid glands always decreases serum PTH levels. However, there are
often 5 or more parathyroid glands, and mediastinal or intrathyroid ectopic parathyroid tu‐
mors sometimes develop. Therefore, pre- and intraoperative detection of parathyroid glands
is essential. The techniques for detecting them include subtotal extirpation, total extirpation,
and total expiration followed by autotransplantation.
8. Conclusion
Clinical evidence regarding CKD-MBD is reported in the literature, and guidelines have
been developed accordingly. Well-controlled serum phosphate, calcium and PTH levels im‐
prove the prognosis of dialysis patients. Many pharmaceuticals aiming to achieve this goal
have been developed and launched. As the pathology of CKD-MBD is elucidated, the prog‐
nosis of dialysis patients and their quality of life will improve.
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